Abstract
Purpose. To evaluate the biologic effects of SU6668 in patients with solid tumors using comprehensive measures of pharmacokinetics (PK), functional imaging, and tissue correlative studies. Experimental design. Eligible patients with tumors accessible for core needle biopsy were treated with SU6668 at doses of 200 or 400 mg/m2/day. Functional computed tomography (CT) scan and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) were performed at baseline and repeated 4 weeks and 12 weeks after treatment for analysis of tumor angiogenesis. The PK was analyzed using a high-performance liquid chromatography assay. Tumor specimens obtained via core needle biopsy at baseline and 4 weeks later were analyzed for the biologic effects of SU6668. Results. Six of a total of seven patients received treatment for at least 3 months and underwent comprehensive correlative studies, including PK, imaging, and tissue biopsy. Functional CT showed that five of six patients had decreased blood flow in tumors in response to treatment, and DCE-MRI results indicated significant change of area under the signal intensity vs. time curve (AUC) and/or maximum slope (maximum rate of signal intensity change) in two of four patients evaluated with this technique. PK studies showed that the mean apparent oral clearance (Cloral) measured on day 1 was 6.3 ± 2.7 L/hr/m2, yielding a mean AUC of 16.6 ± 4.3 mg/L·hr. By day 22, the Cloral was 40% more than that observed on day 1. Conclusion. It is feasible to evaluate the biologic effects of antiangiogenic agents using comprehensive surrogate measures.
Similar content being viewed by others
References
Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364, 1996
Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocrine Reviews 18: 4–25, 1997
Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435–439, 1996
Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439–442, 1996
Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A: Glioblastoma growth inhibited in vivoby a dominant-negative Flk-1 mutant. Nature 10: 576–579, 1994
Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM: Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res 56: 1615–1620, 1996
Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Senger DR, Dvorak HF: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 53: 4727–4735, 1993
Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM: Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964–3968, 1995
Ellis LM, Takahashi Y, Fenoglio CJ, Cleary KR, Bucana CD, Evans DB: Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 34: 337–340, 1998
Fontanini G, Faviana P, Lucchi M, Boldrini L, Mussi A, Camacci T, Mariani MA, Angeletti CA, Basolo F, Pingitore R:Ahigh vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 86: 558–563, 2002
Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP: Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 56: 2013–2016, 1996
CrewJP, O'Brien T, Bradburn M, Fuggle S, Bicknell R, Cranston D, Harris AL: Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 57: 5281–5285, 1997
Takahashi A, Sasaki H, KimSJ, Tobisu K, KakizoeT, Tsukamoto T, Kumamoto Y, Sugimura T, Terada M: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 54: 4233–4237
Takahashi Y, Bucana CD, Liu W, Yoneda J, Kitadai Y, Cleary KR, Ellis LM: Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: Role of infiltrating cells. J Natl Cancer Inst 88: 1146–1151, 1996
Reinmuth N, LiuW, Jung YD, Ahmad SA, Shaheen RM, Fan F, Bucana CD, McMahon G, Gallick GE, Ellis LM: Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J 15: 1239–1241, 2001
Wang Y, Becker D: Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 3: 887–893, 1997
Laird AD, Christensen JG, Li G, Carver J, Smith K, Xin X, Moss KG, Louie SG, Mendel DB, Cherrington JM: SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J 16: 681–690, 2002
Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G: Cherrington. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60: 4152–4160, 2000
Shaheen RM, Tseng WW, Davis DW, Liu W, Reinmuth N, Vellagas R, Wieczorek AA, Ogura Y, McConkey DJ, Drazan KE, Bucana CD, McMahon G, Ellis LM: Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 61: 1464–1468, 2001
Dancey J, Sausville EA: Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2: 296–313, 2003
Rowinsky EK: Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies. J Clin Oncol 21(10 Suppl): 175–186, 2003
DavisDW, McConkey DJ, Abbruzzese JL, Herbst RS: Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 89: 8–14, 2003
Brahmer JR, Kelsey S, Scigalla P, Hill G, Bello C, Elza-Brown K, Donehower R: A phase I study of SU6668 in patients with refractory solid tumors. Proc Am Soc Clin Oncol Abstract 335, 2002
Grasselli G, Baselga J, Sessa C, Viganó L, Locatelli A, Trigo J, Lladó A, Scigalla P, Kelsey S, Colombini S, Marsoni S, Gianni L: Dose-escalation and pharmacologic study of oral SU-006668 in patients with advanced solid tumors. ProcAmSoc Clin Oncol Abstract 67, 2002
Kuenen B, Ruijter R, Hoekman K, Scigalla P, Giaccone G, Pinedo H: Dose finding study of SU6668 given thrice daily by oral route under fed conditions in patients with advanced malignancies. Proc Am Soc Clin Oncol Abstract 437, 2002
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Xiong, H.Q., Herbst, R., Faria, S.C. et al. A phase I surrogate endpoint study of SU6668 in patients with solid tumors. Invest New Drugs 22, 459–466 (2004). https://doi.org/10.1023/B:DRUG.0000036688.96453.8d
Issue Date:
DOI: https://doi.org/10.1023/B:DRUG.0000036688.96453.8d